BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax of -$10.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-06-30 was -$10.00M, a 116.95% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-03-31 was -$29.00M, a 137.66% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-06-30 was $59.00M, a 195.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-03-31 was $77.00M, a 413.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2025 was $88.00M, a 166.67% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2024 was $33.00M, a 90.12% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2023 was $334.00M, a 36.26% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2022 was $524.00M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.00M 10-Q · filed 2026-07-30 | -$39.00M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | -$29.00M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $88.00M 10-K · filed 2026-02-11 | |||
| 2025-06-30 | $59.00M 10-Q · filed 2026-07-30 | $136.00M 10-Q · filed 2026-07-30 | $76.00M derived: sum of 3 quarters · filed 2026-07-30 | $134.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $77.00M 10-Q · filed 2026-04-30 | $17.00M derived: sum of 2 quarters · filed 2026-04-30 | $75.00M derived: sum of 3 quarters · filed 2026-04-30 | $95.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$2.00M derived: sum of 2 quarters · filed 2026-02-11 | $18.00M derived: sum of 3 quarters · filed 2026-02-11 | $33.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $58.00M 10-Q · filed 2024-10-31 | $78.00M derived: sum of 2 quarters · filed 2024-10-31 | $93.00M 10-Q · filed 2024-10-31 | $192.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $20.00M 10-Q · filed 2024-07-26 | $35.00M 10-Q · filed 2024-07-26 | $134.00M derived: sum of 3 quarters · filed 2026-02-11 | $150.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $15.00M 10-Q · filed 2025-04-24 | $114.00M derived: sum of 2 quarters · filed 2026-02-11 | $130.00M derived: sum of 3 quarters · filed 2026-02-11 | $216.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $115.00M derived: sum of 2 quarters · filed 2026-02-11 | $201.00M derived: sum of 3 quarters · filed 2026-02-11 | $334.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $16.00M 10-Q · filed 2024-10-31 | $102.00M derived: sum of 2 quarters · filed 2024-10-31 | $235.00M 10-Q · filed 2024-10-31 | $368.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $86.00M 10-Q · filed 2024-07-26 | $219.00M 10-Q · filed 2024-07-26 | $352.00M derived: sum of 3 quarters · filed 2025-02-12 | $527.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $133.00M 10-Q · filed 2024-04-25 | $266.00M derived: sum of 2 quarters · filed 2025-02-12 | $441.00M derived: sum of 3 quarters · filed 2025-02-12 | $572.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $308.00M derived: sum of 2 quarters · filed 2025-02-12 | $439.00M derived: sum of 3 quarters · filed 2025-02-12 | $524.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $175.00M 10-Q · filed 2023-10-26 | $306.00M derived: sum of 2 quarters · filed 2023-10-26 | $391.00M 10-Q · filed 2023-10-26 | $422.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $131.00M 10-Q · filed 2023-07-27 | $216.00M 10-Q · filed 2023-07-27 | $247.00M derived: sum of 3 quarters · filed 2024-02-13 | $210.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $85.00M 10-Q · filed 2023-04-27 | $116.00M derived: sum of 2 quarters · filed 2024-02-13 | $79.00M derived: sum of 3 quarters · filed 2024-02-13 | $26.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$6.00M derived: sum of 2 quarters · filed 2024-02-13 | -$59.00M derived: sum of 3 quarters · filed 2024-02-13 | -$95.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | -$37.00M 10-Q · filed 2022-10-26 | -$90.00M derived: sum of 2 quarters · filed 2022-10-26 | -$126.00M 10-Q · filed 2022-10-26 | -$141.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$53.00M 10-Q · filed 2022-07-27 | -$89.00M 10-Q · filed 2022-07-27 | -$104.00M derived: sum of 3 quarters · filed 2023-02-14 | -$87.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$36.00M 10-Q · filed 2022-04-29 | -$51.00M derived: sum of 2 quarters · filed 2023-02-14 | -$34.00M derived: sum of 3 quarters · filed 2023-02-14 | -$2.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $2.00M derived: sum of 2 quarters · filed 2023-02-14 | $34.00M derived: sum of 3 quarters · filed 2023-02-14 | $54.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | $17.00M 10-Q · filed 2021-10-27 | $49.00M derived: sum of 2 quarters · filed 2021-10-27 | $69.00M 10-Q · filed 2021-10-27 | $96.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $32.00M 10-Q · filed 2021-07-28 | $52.00M 10-Q · filed 2021-07-28 | $79.00M derived: sum of 3 quarters · filed 2022-02-09 | $99.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $20.00M 10-Q · filed 2021-04-29 | $47.00M derived: sum of 2 quarters · filed 2022-02-09 | $67.00M derived: sum of 3 quarters · filed 2022-02-09 | $93.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $47.00M derived: sum of 2 quarters · filed 2022-02-09 | $73.00M derived: sum of 3 quarters · filed 2022-02-09 | $103.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $20.00M 10-Q · filed 2020-11-05 | $46.00M derived: sum of 2 quarters · filed 2020-11-05 | $76.00M 10-Q · filed 2020-11-05 | $100.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $26.00M 10-Q · filed 2020-08-06 | $56.00M 10-Q · filed 2020-08-06 | $80.00M derived: sum of 3 quarters · filed 2021-02-10 | $93.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $30.00M 10-Q · filed 2020-05-07 | $54.00M derived: sum of 2 quarters · filed 2021-02-10 | $67.00M derived: sum of 3 quarters · filed 2021-02-10 | $54.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $37.00M derived: sum of 2 quarters · filed 2021-02-10 | $24.00M derived: sum of 3 quarters · filed 2021-02-10 | $4.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $13.00M 10-Q · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | -$20.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$13.00M 10-Q · filed 2019-07-25 | -$33.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | -$20.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | -$19.00M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | -$12.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |